AU2018383664B2 - Cancer vaccines targeting Survivin and uses thereof - Google Patents

Cancer vaccines targeting Survivin and uses thereof Download PDF

Info

Publication number
AU2018383664B2
AU2018383664B2 AU2018383664A AU2018383664A AU2018383664B2 AU 2018383664 B2 AU2018383664 B2 AU 2018383664B2 AU 2018383664 A AU2018383664 A AU 2018383664A AU 2018383664 A AU2018383664 A AU 2018383664A AU 2018383664 B2 AU2018383664 B2 AU 2018383664B2
Authority
AU
Australia
Prior art keywords
seq
set forth
sequence set
nucleic acid
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018383664A
Other languages
English (en)
Other versions
AU2018383664A1 (en
Inventor
Neil COOCH
Bradley GARMAN
Anna SLAGER
Jian Yan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inovio Pharmaceuticals Inc
Original Assignee
Inovio Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inovio Pharmaceuticals Inc filed Critical Inovio Pharmaceuticals Inc
Publication of AU2018383664A1 publication Critical patent/AU2018383664A1/en
Priority to AU2024264712A priority Critical patent/AU2024264712A1/en
Application granted granted Critical
Publication of AU2018383664B2 publication Critical patent/AU2018383664B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2018383664A 2017-12-13 2018-12-13 Cancer vaccines targeting Survivin and uses thereof Active AU2018383664B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024264712A AU2024264712A1 (en) 2017-12-13 2024-11-18 Cancer vaccines targeting survivin and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762598267P 2017-12-13 2017-12-13
US62/598,267 2017-12-13
PCT/US2018/065529 WO2019118766A2 (en) 2017-12-13 2018-12-13 Cancer vaccines targeting survivin and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024264712A Division AU2024264712A1 (en) 2017-12-13 2024-11-18 Cancer vaccines targeting survivin and uses thereof

Publications (2)

Publication Number Publication Date
AU2018383664A1 AU2018383664A1 (en) 2020-07-16
AU2018383664B2 true AU2018383664B2 (en) 2024-12-05

Family

ID=66734396

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018383664A Active AU2018383664B2 (en) 2017-12-13 2018-12-13 Cancer vaccines targeting Survivin and uses thereof
AU2024264712A Pending AU2024264712A1 (en) 2017-12-13 2024-11-18 Cancer vaccines targeting survivin and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024264712A Pending AU2024264712A1 (en) 2017-12-13 2024-11-18 Cancer vaccines targeting survivin and uses thereof

Country Status (11)

Country Link
US (2) US12064473B2 (enExample)
EP (1) EP3723793A4 (enExample)
JP (3) JP7385569B2 (enExample)
KR (2) KR102648079B1 (enExample)
CN (1) CN111479583A (enExample)
AU (2) AU2018383664B2 (enExample)
BR (1) BR112020011820A2 (enExample)
CA (1) CA3083534A1 (enExample)
MX (2) MX2020006285A (enExample)
RU (1) RU2751253C1 (enExample)
WO (1) WO2019118766A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020011820A2 (pt) * 2017-12-13 2020-11-17 Inovio Pharmaceuticals, Inc. moléculas de ácido nucleico e seus usos, vetor, composições, proteínas e vacinas

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002211490A1 (en) 2000-10-04 2002-04-15 The Trustees Of The University Of Pennsylvania Compositions and methods of using capsid protein from flaviviruses and pestiviruses
US20110223187A1 (en) * 2010-02-15 2011-09-15 Vafa Shahabi Live listeria-based vaccines for central nervous system therapy
AU2013243954A1 (en) * 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
CN106456735B (zh) 2014-03-28 2021-06-29 华盛顿大学商业中心 乳腺癌和卵巢癌疫苗
RU2749113C2 (ru) * 2015-04-22 2021-06-04 Куревак Аг Содержащая рнк композиция для лечения опухолевых заболеваний
WO2016179573A1 (en) * 2015-05-07 2016-11-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Variant survivin vaccine for treatment of cancer
TW201723171A (zh) * 2015-09-15 2017-07-01 艾法西斯公司 基於李斯特菌屬之免疫原性組成物及其於癌症預防與治療中之使用方法
BR112020011820A2 (pt) * 2017-12-13 2020-11-17 Inovio Pharmaceuticals, Inc. moléculas de ácido nucleico e seus usos, vetor, composições, proteínas e vacinas

Also Published As

Publication number Publication date
JP2021506265A (ja) 2021-02-22
CN111479583A (zh) 2020-07-31
KR102648079B1 (ko) 2024-03-18
US20190175707A1 (en) 2019-06-13
MX2025004799A (es) 2025-05-02
EP3723793A4 (en) 2022-01-19
US12064473B2 (en) 2024-08-20
JP7385569B2 (ja) 2023-11-22
MX2020006285A (es) 2020-09-17
EP3723793A2 (en) 2020-10-21
CA3083534A1 (en) 2019-06-20
KR20200096957A (ko) 2020-08-14
JP2025092647A (ja) 2025-06-19
AU2024264712A1 (en) 2024-12-05
AU2018383664A1 (en) 2020-07-16
US20240358809A1 (en) 2024-10-31
BR112020011820A2 (pt) 2020-11-17
WO2019118766A3 (en) 2019-09-19
KR20240038139A (ko) 2024-03-22
RU2021117812A3 (enExample) 2021-11-08
JP2023155245A (ja) 2023-10-20
RU2751253C1 (ru) 2021-07-12
WO2019118766A2 (en) 2019-06-20
JP7659599B2 (ja) 2025-04-09
RU2021117812A (ru) 2021-07-26

Similar Documents

Publication Publication Date Title
AU2022203986A1 (en) Cancer vaccines targeting PRAME and uses thereof
US20240358809A1 (en) Cancer vaccines targeting survivin and uses thereof
AU2018383662B2 (en) Cancer vaccines targeting MUC16 and uses thereof
US11986517B2 (en) Cancer vaccines targeting mesothelin and uses thereof
RU2776949C2 (ru) Противораковые вакцины, нацеленные на сурвивин, и их применения
US12161706B2 (en) Cancer vaccines targeting BORIS and uses thereof
RU2830879C2 (ru) Мезотелин-нацеленные вакцины от рака и их применение
CA3084137A1 (en) Cancer vaccines targeting lemd1 and uses thereof
HK40034681A (en) Cancer vaccines targeting survivin and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)